ADP-ribosylating adjuvant |
|
Vaxjo ID |
276 |
|
Vaccine Adjuvant Name |
ADP-ribosylating adjuvant |
|
Adjuvant VO ID |
VO_0005764
|
|
Description |
A genetically engineered fusion protein comprising the ADP-ribosylating CTA1 enzyme from cholera toxin fused to a CD103-targeting scFv antibody and vaccine antigens (e.g., M2e or OVA epitopes) |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
We genetically engineered a vaccine adjuvant platform that targeted the cholera toxin A1 (CTA1) ADP-ribosylating enzyme to CD103+ cDC1 and cDC2 cells using a single-chain antibody (scFv) to CD103. |
|
Structure |
Fusion protein containing CTA1 enzyme + CD103-targeting scFv + inserted antigen peptide (e.g., SIINFEKL or M2e) |
|
Preparation |
Expressed recombinantly (e.g., in E. coli), purified via affinity chromatography; enzymatic activity verified by in vitro assays |
|
Dosage |
Intranasal (i.n.) administration in mice; typically 5 µM per dose, given in 1–3 doses |
|
Function |
Migratory dendritic cells expressing CD103 are the targets for mucosal vaccines. These belong to either of two lineage-restricted subsets, cDC1 or cDC2 cells, which have been linked to priming of functionally distinct CD4 T cells |
|
Safety |
No adverse effects reported in mouse studies |
| References |
Arabpour et al., 2022: Arabpour M, Lebrero-Fernandez C, Schön K, Strömberg A, Börjesson V, Lahl K, Ballegeer M, Saelens X, Angeletti D, Agace W, Lycke N. ADP-ribosylating adjuvant reveals plasticity in cDC1 cells that drive mucosal Th17 cell development and protection against influenza virus infection. Mucosal immunology. 2022; 15(4); 745-761. [PubMed: 35418673].
|
